Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics ThruPLEX Plasma-Seq Kit

Rubicon Genomics has launched its ThruPLEX Plasma-seq kit for the preparation of DNA libraries to analyze cell-free DNA found in plasma and other biofluids. The new kit is designed for Illumina next-generation sequencing platforms and has been evaluated by researchers at the Karolinska Institute and Cancer Research UK.

ThruPLEX Plasma-seq has a simple and fast workflow, requiring only three steps in a single tube and two hours of time, with no purification or sample transfers, and yields highly reproducible NGS libraries from less than 1 nanogram and up to 30 nanograms of cell-free DNA in plasma. The optimized repair and ligation chemistries and a modified protocol provide higher library diversity at low input amounts and broad and consistent GC coverage, Rubicon said. The kit is intended for use with plasma samples for applications including analysis of circulating tumor DNA using whole-genome, whole-exome, and targeted gene sequencing, as well as for non-invasive prenatal testing.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.